UroGen Pharma Ltd. (LON: 0XOD)

Market Cap	344.35M
Revenue (ttm)	66.67M
Net Income (ttm)	-86.08M
Shares Out	n/a
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,147
Average Volume	1,439
Open	10.42
Previous Close	10.33
Day's Range	10.07 - 10.44
52-Week Range	8.19 - 16.26
Beta	n/a
RSI	42.17
Earnings Date	Mar 14, 2025

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 201
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0XOD

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Financial numbers in USD